These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2003508)

  • 41. ASHP guidelines for implementing and obtaining compensation for clinical services by pharmacists.
    Am J Hosp Pharm; 1985 Jul; 42(7):1581-2. PubMed ID: 4025362
    [No Abstract]   [Full Text] [Related]  

  • 42. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-approval inspections/investigations. Food and Drug Administration.
    J Parenter Sci Technol; 1991; 45(1):56-66. PubMed ID: 2007970
    [No Abstract]   [Full Text] [Related]  

  • 44. Guidelines on gifts to physicians from industry: an update.
    American Medical Association. Council on Ethical and Judicial Affairs
    Food Drug Law J; 1992; 47(4):445-58. PubMed ID: 11654909
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond prescription benefits management: the systems approach to patient and pharmaceutical care.
    Thomas N; Larson LN; Bell NN
    Empl Benefits J; 1995 Mar; 21(1):2-8, 29. PubMed ID: 10156575
    [No Abstract]   [Full Text] [Related]  

  • 46. The ostrich syndrome in American pharmacy.
    Whitney HA
    Ann Pharmacother; 2006 Jan; 40(1):115. PubMed ID: 16397304
    [No Abstract]   [Full Text] [Related]  

  • 47. Approved: revised Public Information Policy.
    Joint Commission on Accreditation of Healthcare Organizations
    Jt Comm Perspect; 2007 Oct; 27(10):5-8. PubMed ID: 17993199
    [No Abstract]   [Full Text] [Related]  

  • 48. Considering experimentation and elusive truth: informed consent made difficult.
    Brodeur D
    Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
    [No Abstract]   [Full Text] [Related]  

  • 49. Violence prevention at the health care site.
    Felton JS
    Occup Med; 1997; 12(4):701-15. PubMed ID: 9353818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 51. "Disclosure of retail prices for prescription drugs". Response of the American Pharmaceutical Association to the June 14, 1974, inquiry of the Federal Trade Commission.
    J Am Pharm Assoc; 1974 Oct; 14(10):538-42, 577-8. PubMed ID: 4418393
    [No Abstract]   [Full Text] [Related]  

  • 52. Barriers to clinical trials vary according to the type of trial and the institution.
    Govindarajan R; Young JW; Harless CL; Hutchins LF
    J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
    [No Abstract]   [Full Text] [Related]  

  • 53. ASHP says patient counseling is pharmacist's obligation.
    Oddis J
    Hosp Formul; 1978 Jul; 13(7):534. PubMed ID: 10308292
    [No Abstract]   [Full Text] [Related]  

  • 54. Establishing guidelines on pharmaceutical company support.
    Lane SM
    Am J Hosp Pharm; 1992 May; 49(5):1108, 1110. PubMed ID: 1595731
    [No Abstract]   [Full Text] [Related]  

  • 55. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy.
    Am J Health Syst Pharm; 1995 Feb; 52(4):417-9. PubMed ID: 7757870
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical research: ASHP guidelines and future directions for pharmacists.
    Phillips MS
    Am J Health Syst Pharm; 1999 Feb; 56(4):344-6. PubMed ID: 10690218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interpretation of standards.
    Kessler H
    Hosp Pharm; 1976 May; 11(5):168. PubMed ID: 1026701
    [No Abstract]   [Full Text] [Related]  

  • 58. ASCP reports: a good year for championing the cause of consultant pharmacists.
    Jayaprakash A
    Consult Pharm; 2010 Jan; 25(1):66. PubMed ID: 20211818
    [No Abstract]   [Full Text] [Related]  

  • 59. Dispensing investigational drugs: regulatory issues and the role of the investigational drug service.
    Shehab N; Tamer H
    Am J Health Syst Pharm; 2004 Sep; 61(18):1882-4. PubMed ID: 15487876
    [No Abstract]   [Full Text] [Related]  

  • 60. Report of the ASHP Task Force on Organizational Structure.
    ASHP Task Force on Organizational Structure
    Am J Health Syst Pharm; 2014 Jun; 71(12):1049-54. PubMed ID: 24865763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.